Trials / Recruiting
RecruitingNCT06222671
A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of 608 in Patients With Non-radiographic Axial Spondyloarthritis (Nr-axSpA)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the effect and safety of 608 in patients with nr-axSpA.
Detailed description
The purpose of this study is to demonstrate the clinical efficacy, safety and tolerability of 608 compared to placebo in patients with nr-axSpA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 608 | 608 subcutaneous (SC) injection. |
| DRUG | 608 | 608 subcutaneous (SC) injection. |
| DRUG | Placebo | Placebo subcutaneous (SC) injection. |
Timeline
- Start date
- 2024-03-22
- Primary completion
- 2025-09-22
- Completion
- 2025-11-30
- First posted
- 2024-01-25
- Last updated
- 2025-03-11
Locations
6 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06222671. Inclusion in this directory is not an endorsement.